Home › Companies › SPRB

Spruce Biosciences

Market cap $116M 2.9M shares (10-Q, Nov 5, 2026) × $40.49 close Nov 17, 2026

Most recent annual filing: 2026-03-09

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. TA-ERT tralesinidase alfa BLA filingDec 2026TA-ERT tralesinidase alfa BLA filing, Dec 2026, major
  2. Avenue Tranche 2 renegotiated corporateJan 1 – Mar 31, 2027Avenue Tranche 2 renegotiated corporate, Jan 1 – Mar 31, 2027, routine
  3. Adrenyx Biosciences CRHX-101 spin-out corporate1H 2027Adrenyx Biosciences CRHX-101 spin-out corporate, 1H 2027, routine
  4. Avenue Tranche 3 corporate updateJul–Dec 2027Avenue Tranche 3 corporate update, Jul–Dec 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Discontinued (1)

Capital (as filed)

Cash
$87.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$13.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$87.7M cash, runway second half of 2027 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Spruce Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Spruce Biosciences (SPRB) - Scientific Deep Dive for Tralesinidase and Pipeline Products Science is sound and capital raises remove near-term bankruptcy risk, but confirmation of successful CMC/PPQ batch manufacturing is needed before initiating a position ahead of the Q4 BLA submission.
  2. Speculative buy speculative UPDATE: Spruce Biosciences (SPRB) - They Hired the Man Who Launched Brineura A 25.8% drawdown on zero news combined with a credible permanent CMO hire (Brineura/NAGLAZYME/VIMIZIM launch veteran) and a 9.1% institutional holder justify a starter speculative position, though PPQ batch confirmation remains outstanding.
  3. Speculative buy speculative UPDATE: Spruce Biosciences (SPRB) - The Patients Just Bought the Stock Advocacy foundations' $5.5M equity purchase, a second Brineura veteran hire, and a funded EAP rehearsal for commercial delivery all corroborate the Q4 BLA timeline, but PPQ batch confirmation remains outstanding so position stays starter-sized.
  4. Buy core UPDATE: Spruce Biosciences (SPRB) - The Factory Signed Off The explicit PPQ batch confirmation condition set in the deep dive is now met — FDA called comparability strategies reasonable, first PPQ batch manufactured, BLA content aligned — justifying an upgrade from speculative starter to core position.
  5. Hold UPDATE: Spruce Biosciences (SPRB) - The Factory Held, The Tranche Didn't Avenue Tranche 2 lapsed undrawn and had to be renegotiated, going-concern language appears in the 10-Q, and dilution before the PDUFA decision now looks likely — downgrading to hold while the regulatory picture (sister MPS surrogate precedent, on-track CMC) remains intact.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

17 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)